MannKind
Manufacturing · Connecticut, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
1 Casper St, Danbury, Connecticut, 06810...Phone Number
(818) 661-5000Website
www.mannkindcorp.comRevenue
$360.8 MillionStock Symbol
MNKDIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
7
1
1
1
2
1
About MannKind
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension.Explore more
MannKind Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MannKind your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
MannKind, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check out if MannKind is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at MannKind
Click to see if MannKind had a recent Job posting/layoffs
Earning: See what the market has to say on MannKind recently announced quarterly report
Check if MannKind has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when MannKind launches new products
Funding: Get notified immidiatlly once MannKind has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to MannKind
Compare insights from companies similar to MannKind, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
MannKind is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
MannKind is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about MannKind.
MannKind financials insights
Gather financial insights about MannKind, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Stock Offering
$36.2M
2016
Stock Offering
$47.5M
2017
Stock Offering
$61M
2018
Stock Offering
$28M
2020
Debt
$2M
2025
Stock/Share Issuance
$500M
2026
Stock/Share Issuance
$50M
MannKind Tech Stack
A closer look at the technologies used by MannKind
See more technologies
Most Recent Scoops
Project
MannKind has announced plans to launch high-dose concentration cartridges, a new product enhancement targeting the Type 2 diabetes market, expected to be available in approximately 2028.
Open Position
Person-Based
Automation, Manufacturing Operations
Open Position
Open Position
MannKind News & Media
MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that the Company will report second quarter 2026 financial results after market close on Wednesday, August 5, 2026.MannKind (Nasdaq: MNKD) gains FDA nod, secures $50M financing - Stock Titan
MannKind completes $50M private placement of stock and pre-funded warrants, then plans a $45M CVR payment following FDA approval of Furoscix ReadyFlow.MannKind Corporation (MNKD) Discusses FDA Approval of Furoscix ReadyFlow for IV-Equivalent Diuretic Therapy in Fluid Overload Transcript
MannKind Corporation (MNKD) Discusses FDA Approval of Furoscix ReadyFlow for IV-Equivalent Diuretic Therapy in Fluid Overload July 24, 2026 9:00 AM...MannKind closes $50M financing, wins FDA nod for Furoscix auto-injector - MassDevice
MannKind (Nasdaq:MNKD) announced today that it secured $50 million in a private placement and earned a new regulatory nod.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MannKind
Sign Up For FreeTo access detailed company insights
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery dev... Read More
